Successful participation at ISPAD 2024

myLoop offers the solution for tailored care for children as well as for an individualized therapy management during exercise. Professor Sabine Hofer and Professor Othmar Moser demonstrated how myLoop powered by CamAPS FX effectively manages a higher day-to-day variation of insulin needs of very young children with type 1 diabetes or during exercise by providing practical guidance on the CamAPS FX system.

Key take home messages:

• myLoop powered by CamAPS FX provides optimal glycemic management in very young children with type 1 diabetes from onset to minimize early onset diabetes associated with a high lifetime risk of diabetes complications.¹

• myLoop is valuable and needs to be made available to children with type 1 diabetes at a very young age, as they generally have a higher day-to-day variability of insulin requirements, according to Prof. Sabine Hofer (ISPAD 2024)

• myLoop powered by CamAPS FX offers many opportunities to individualize therapy around exercise, which should be adjusted according to the glucose response to exercise.²

• Most therapy adjustments should be made 60-120 minutes before exercise, although spontaneous exercise is possible but will result in higher carbohydrate amounts during exercise. However, myLoop is safe to use even during moderate exercise.²

• Important for a successful application of myLoop for very young children and adolescents with type 1 diabetes is the education and training of team members, parents and nursery staff.

In our sessions, Professor Sabine Hofer and Professor Othmar Moser explained how AID systems such as myLoop best support very young children and adolescents with type 1 diabetes in their daily glucose management challenges or during exercise.

CamAPS FX delivered sustained and clinically significant improvements in glycemic management over 18 months in very young children with type 1 diabetes, demonstrating the longer-term safety and glycemic benefits of hybrid closed-loop therapy in this age group, according to results from an extension phase study.³ Additionally, semi-structured interviews with parents of very young children with type 1 diabetes using hybrid closed-loop systems report a more normal parent/child/family experience.⁴

Professor Sabine Hofer emphasised that the myLoop system is a well-studied option for young children with diabetes, with the potential to be utilised from the disease onset in very young children. While the remission phase may present certain challenges, myLoop offers a viable approach to managing it.

Professor Othmar Moser presented data demystifying exercise for people with type 1 diabetes and making it available to everyone by showing that myLoop offers numerous opportunities to individualize therapy around exercise.